BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Klogenix LLC (“Klogenix” or “the Company”) is pleased to announce that its intellectual property portfolio has been acquired by ADvantage Therapeutics, Inc. and co-founder Dr. Carmela R. Abraham, Ph.D. has been appointed Chief Science Officer at the acquiring company.

波士顿，2023年10月2日（GLOBE NEWSWIRE）-Klogenix LLC（“Klogenix”或“the Company”）很高兴地宣布其知识产权组合已被ADvantage Therapeutics，Inc。和共同创始人Carmela R.Abraham博士，博士被任命为收购公司的首席科学官。

Dr. Abraham, a distinguished luminary in the fields of Alzheimer’s disease and aging, brings her wealth of knowledge and pioneering work on the Klotho protein to the forefront of ADvantage’s strategic vision. ADvantage Therapeutics Inc. is currently entering confirmatory Phase 2b clinical trials with its AD04 Alzheimer’s drug candidate, developed at its labs at the Vienna, Austria, BioCenter.

亚伯拉罕博士是阿尔茨海默病和衰老领域的杰出人物，她将Klotho蛋白的丰富知识和开创性工作带到了优势战略愿景的最前沿。ADvantage Therapeutics Inc.目前正在其AD04阿尔茨海默氏症候选药物进入2b期临床试验的确证阶段，该药物由奥地利维也纳生物中心的实验室开发。

Commenting on her new role, Dr. Abraham stated, “Through ADvantage Therapeutics’ pioneering compound AD04, and our exploration of the Klotho protein's applications, we are at the forefront of redefining approaches to combat Alzheimer’s disease and the aging process. Having dedicated my entire career to these goals, I am delighted to join the talented team of scientists at ADvantage and contribute to addressing some of the most complex challenges that affect the human body and mind.

亚伯拉罕博士在评论她的新角色时说， “通过ADvantage Therapeutics的开创性化合物AD04，以及我们对Klotho蛋白应用的探索，我们处于重新定义对抗阿尔茨海默病和衰老过程的方法的前沿。将我的整个职业生涯奉献给这些目标，我很高兴加入有才能的科学家团队，并为解决一些最复杂的ch做出贡献影响人体和心灵的挑战。

I eagerly anticipate our collaborative journey ahead.' AD04™ is a novel disease modifying immunomodulator for mild Alzheimer’s Disease. The compound has been shown in a previous trial to significantly slow the decline in patients’ cognition and quality of life as well as slow the decline in hippocampal volume (as a biomarker).

我热切期待我们未来的合作旅程。”AD04™ 是一种用于轻度阿尔茨海默病的新型疾病调节免疫调节剂。在先前的试验中已经显示该化合物显着减缓患者认知和生活质量的下降以及减缓海马体积的下降（作为生物标志物）。

ADvantage Therapeutics, Inc. believes AD04™ stimulates and/or regulates the immune system to reduce Alzheimer’s pathology. ADvantage Therapeutics is dedicated to advancing the science of neurodegenerative diseases and committed to developing innovative therapies that can mak.

ADvantage Therapeutics，Inc.相信AD04™ 刺激和/或调节免疫系统以减少阿尔茨海默病的病理。ADvantage Therapeutics致力于推进神经退行性疾病的科学，并致力于开发可以制造的创新疗法。